Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) approved in the US for the treatment of COPD

Approval was based on the ETHOS Phase III study in which it reduced the rate of moderate-severe exacerbations versus dual combination therapies (glycopyrrolate/formoterol fumarate and budesonide/formoterol fumarate). It is currently under regulatory review in the EU.

PharmaTimes